Kamada KMDA
NASDAQ KMDA
$8.21 -0.08 (-0.97%)
As of: Sep 9, 2026 · 3:35 PM EDT

Kamada (KMDA) Operating Income (2012 - 2026)

Kamada's (KMDA) quarterly Operating Income came in at $9.5 million in Q2 2026, up 34.49% on a YoY basis from $7.1 million in Q2 2025, and up 36.78% quarter-over-quarter from $7.0 million in Q1 2026.

Analysis

Kamada (KMDA) Operating Income (2012 - 2026) Analysis & Trends

Kamada (KMDA) has reported Operating Income for 15 consecutive years, with $9.5 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Operating Income rose 34.49% year-over-year to $9.5 million; the trailing twelve-month figure through Jun 2026 stood at $27.8 million (up 10.27% YoY), and the FY2025 full-year result was $26.2 million, up 30.83% from the prior year.
  • Operating Income climbed to $9.5 million in Q2 2026 per KMDA's latest filing, from $7.0 million in the prior quarter.
  • Across five years, Operating Income topped out at $9.5 million in Q2 2026 and bottomed at -$2.3 million in Q2 2022.
  • Historically, Operating Income has averaged $4.3 million across 5 years, with a median of $4.2 million in 2023.
  • The sharpest annual moves came in 2022 and 2024: Operating Income tumbled 319.31% in 2022, then jumped 1297.58% in 2024.
  • Over 5 years, Operating Income stood at $4.0 million in 2022, then plunged by 30.91% to $2.8 million in 2023, then surged by 82.93% to $5.1 million in 2024, then sank by 30.07% to $3.6 million in 2025, then soared by 167.81% to $9.5 million in 2026.
  • According to Business Quant data, Operating Income over the past three periods registered $9.5 million, $7.0 million, and $3.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Op. Inc (Qtr)
1 Amgen 211.77 Bn 197.79 Bn 7.24 Bn 3.51 Bn
2 Gilead Sciences 181.13 Bn 177.95 Bn 6.22 Bn -10.39 Bn
3 Vertex Pharmaceuticals 132.24 Bn 124.39 Bn 2.84 Bn 1.25 Bn
4 Regeneron Pharmaceuticals 82.89 Bn 74.89 Bn 3.93 Bn 1.29 Bn
5 Argenx Se 61.56 Bn 56.38 Bn 1.37 Bn 493.00 Mn
6 Moderna 54.38 Bn 49.24 Bn 52.00 Mn -815.00 Mn
7 Alnylam Pharmaceuticals 34.44 Bn 31.13 Bn 992.69 Mn 231.44 Mn
8 Biogen 31.17 Bn 29.89 Bn 1.96 Bn -644.50 Mn
9 Roivant Sciences 30.12 Bn 30.12 Bn 1.16 Mn -365.99 Mn
10 Kamada 473.28 Mn 403.14 Mn 22.47 Mn 9.51 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 9.51 Mn
Mar 31, 2026 6.95 Mn
Dec 31, 2025 3.55 Mn
Sep 30, 2025 7.82 Mn
Jun 30, 2025 7.07 Mn
Mar 31, 2025 7.80 Mn
Dec 31, 2024 5.08 Mn
Sep 30, 2024 5.29 Mn
Jun 30, 2024 5.64 Mn
Mar 31, 2024 4.04 Mn
Dec 31, 2023 2.78 Mn
Sep 30, 2023 4.37 Mn
Jun 30, 2023 2.63 Mn
Mar 31, 2023 289,000.00
Dec 31, 2022 4.02 Mn
Sep 30, 2022 2.56 Mn
Jun 30, 2022 -2.29 Mn
Mar 31, 2022 246,000.00
Dec 31, 2021 -3.30 Mn
Sep 30, 2021 -804,000.00